Sodium-Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes.

Card Fail Rev · 2019 · PMC6848945 · PMID 31768274

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline non-significantno p-value reported

The borderline non-significant results in the non-HFrEF patients were mainly driven by cardiovascular death as in the subgroup analysis; dapagliflozin decreased HF hospitalisation both in patients with HFrEF (HR 0.64; 95% CI [0.43–0.95]) and without HFrEF (HR 0.76; 95% CI [0.62–0.92]).

also in 434 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.